Bioretec
2.73 EUR -0.73%1,323 investors are following this company
Bioretec is a medical technology company. The company specializes in the development of medical devices. The product portfolio includes, for example, implants for pediatric and adult orthopedics and other material for bone and soft tissue injuries. In addition to the main business, service and associated ancillary services are also offered. Bioretec operates worldwide with the largest presence in the Nordic region.
P/E (24e)
-17.09
EV/EBIT (adj.) (24e)
-18.04
P/B (24e)
11.82
Dividend yield-% (24e)
-
Target price
2.80 EUR
Recommendation
Accumulate
Updated
19.2.2024
First North Finland
BRETEC
Daily low / high price
2.69 / 2.78
EUR
Market cap
55.52M EUR
Turnover
42.55K EUR
Volume
16K
Risk and recommendation
HighRiskLow
SellRecommendationBuy
Analyst
Antti Siltanen
Analyst
Latest videos
Financial calendar
General meeting
2024-04-26
Business review
2024-05-16
Interim report
2024-08-15
Business review
2024-11-14
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Stephen Industries Inc Oy | 10.9 % | 10.9 % |
Ilmarinen Mutual Pension Insurance Company | 6.6 % | 6.6 % |
Premium
This content is for our Premium customers only.
Insider Transactions
Insider | Date | Total value |
---|---|---|
Kustaa Poutiainen | 2024-01-03 | 1,273,377EUR |
Kustaa Poutiainen | 2023-10-25 | 840,000EUR |
Premium
This content is for our Premium customers only.
Income statement
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Revenue | 1.5 | 2.0 | 2.9 | 3.9 | 6.2 | 8.7 | 13.0 | 19.7 |
growth-% | -14.2 % | 33.6 % | 46.9 % | 32.8 % | 57.9 % | 41.2 % | 48.7 % | 52.1 % |
EBITDA | -2.1 | -2.8 | -2.0 | -2.8 | -2.5 | -1.3 | 0.8 | 2.4 |
EBIT (adj.) | -1.9 | -2.7 | -2.3 | -3.0 | -2.9 | -2.1 | 0.0 | 1.6 |
EBIT | -1.9 | -2.7 | -2.3 | -3.0 | -2.9 | -2.1 | 0.0 | 1.6 |
Profit before taxes | -2.3 | -6.0 | -2.4 | -3.8 | -3.1 | -2.4 | -0.3 | 1.4 |
Net income | -2.3 | -6.0 | -2.4 | -3.8 | -3.1 | -2.4 | -0.3 | 1.4 |
EPS (adj.) | -0.02 | -0.43 | -0.17 | -0.20 | -0.16 | -0.12 | -0.02 | 0.07 |
growth-% | ||||||||
Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Dividend ratio |
Profitability and return on capital
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
EBITDA-% | -137.8 % | -141.6 % | -68.0 % | -72.6 % | -40.9 % | -15.4 % | 6.0 % | 12.1 % |
EBIT-% (adj.) | -128.4 % | -133.1 % | -77.9 % | -77.7 % | -47.4 % | -23.6 % | 0.1 % | 8.0 % |
EBIT-% | -128.4 % | -133.1 % | -77.9 % | -77.7 % | -47.4 % | -23.6 % | 0.1 % | 8.0 % |
ROE | -4,642.9 % | -211.2 % | -77.8 % | -74.7 % | -49.0 % | -73.9 % | -18.3 % | 57.0 % |
ROI | -90.4 % | -54.8 % | -46.8 % | -42.9 % | -29.1 % | -23.7 % | 0.1 % | 24.6 % |
Valuation
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Share price (EUR) | 2.70 | 1.41 | 2.40 | 2.73 | 2.73 | 2.73 | 2.73 | |
Shares | 150.4 | 14.1 | 14.1 | 19.1 | 19.5 | 19.5 | 19.5 | 19.5 |
Market cap | 38.1 | 19.8 | 45.9 | 53.3 | 53.3 | 53.3 | 53.3 | |
Enterprise value | 33.5 | 20.2 | 41.4 | 52.7 | 55.7 | 56.4 | 55.7 | |
EV/S | - | 16.7 | 6.9 | 10.6 | 8.5 | 6.4 | 4.4 | 2.8 |
EV/EBITDA | - | - | - | - | - | - | 72.6 | 23.4 |
EV/EBIT (adj.) | - | - | - | - | - | - | 5,777.8 | 35.4 |
EV/EBIT | - | - | - | - | - | - | 5,777.8 | 35.4 |
P/E (adj.) | - | - | - | - | - | - | - | 38.7 |
P/E | - | - | - | - | - | - | - | 38.7 |
P/B | - | 8.8 | 10.3 | 5.6 | 11.8 | 25.7 | 30.9 | 17.2 |
P/S | - | 19.0 | 6.7 | 11.8 | 8.6 | 6.1 | 4.1 | 2.7 |
Dividend yield | ||||||||
Equity ratio | 35.0 % | 50.3 % | 55.0 % | 77.2 % | 47.8 % | 26.2 % | 28.2 % | 46.6 % |
Gearing ratio | -16.2 % | -107.1 % | 17.9 % | -54.5 % | -14.0 % | 113.3 % | 179.6 % | 76.5 % |
Quarter data
Q1/23 | Q2/23 | Q3/23 | Q4/23 | 2023 | Q1/24e | Q2/24e | Q3/24e | Q4/24e | |
---|---|---|---|---|---|---|---|---|---|
Revenue | 1.9 | 2.0 | 3.9 | 2.6 | 3.6 | ||||
EBITDA | -1.0 | -1.8 | -2.8 | -1.6 | -1.0 | ||||
EBIT | -1.2 | -1.8 | -3.0 | -1.8 | -1.2 | ||||
Profit before taxes | -2.1 | -1.7 | -3.8 | -1.9 | -1.3 | ||||
Net income | -2.1 | -1.7 | -3.8 | -1.9 | -1.3 |
ShowingAll content types
Inside information: Bioretec's RemeOs™ biodegradable magnesium alloy composition has been allowed a patent by the U.S. Patent office
Bioretec Ltd's Annual Report and Financial Statements 2023 published
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools